Association of statin use and disease specific survival for women with type II endometrial cancers: Retrospective analysis of a 15-year experience

Arsdale, A.R. Van; Strickler, Howard D.; Goldberg, Gary L.; Nevadunsky, Nicole S.

doi:10.1016/j.ygyno.2017.03.158

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our analysis included a total of nine observational studies, involving more than 30,141 participants, 5923 of whom were patients with EC who took statins. Eight studies were cohort studies, [16,32–35,37–39] and 1 study was a case–control study. [36] Five articles studied the relationship between the use of statins and the disease-specific survival of endometrial cancer, [16,32,33,38,39] 3 articles discussed the overall survival, [34,36,37] and 1 article considered the overall survival and progression-free survival.…”

Section: Resultsmentioning

confidence: 99%

“…[35] One of these studies was published in the form of an abstract. [39] Most of them were published from 2013 to 2017, with 5 studies in the United States, [16,33–35,39] 1 study in Britain, [32] 1 in Austria, [37] 1 in Denmark [38] and another 1 in Israel. [36] Most individual studies had matched or adjusted variables, including age at diagnosis, tumor stage, tumor grade, BMI, year of diagnosis, race, diabetes status, and smoking history.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The association between statin use and endometrial cancer survival outcome

Liu

Sun

et al. 2018

Medicine

View full text Add to dashboard Cite

Background: Previous studies on the association between statin use and survival outcomes in gynecologic cancers have presented conflicting results. No independent studies to elucidate the association between statin use and survival outcomes of endometrial cancer (EC) have been conducted. Methods: To gather updated evidence, we carried out an extensive literature search on Medline (PubMed and OvidSP), Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), wanfang data, and Vip network to identify all potential studies on the effect of statins on the prognosis of endometrial carcinoma. The design and quality of all studies were evaluated, and a fixed-effects model was used to calculate pooled hazard ratios (HRs) for overall survival (OS) and disease-specific survival (DSS). Results: Of the 219 articles screened, 9 articles were eligible, including 8 articles and 1 abstract. A total of 5923 patients with endometrial cancer who used statins were identified. Statin use was related to increased overall survival (HR, 0.80; 95% confidence interval [CI], 0.66–0.95, without significant heterogeneity, I 2 = 52%, P = .080). Statin users also had increased disease-specific survival (HR, 0.69; 95% CI, 0.61–0.79, I 2 = 0.0%). Conclusion: Statins are beneficial to the survival outcome of patients with endometrial cancer. The selection of statins as a 1st-line agent seems justified for endometrial carcinoma.

show abstract